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29 
Abstract 30 
Chitosan nanoparticles prepared by ionotropic gelation with the 31 
tripolyphosphate (TPP) polyanion have been widely considered for drug 32 
delivery.  The stability (shelf-life) of TPP-chitosan nanoparticles is highly 33 
relevant to its potential use as a drug delivery agent as this plays an important 34 
role in the function of the nanoparticle and will determine shelf-life.  In the 35 
present study, the physical stability (in terms of particle size) of TPP-chitosan 36 
nanoparticles was measured across a range of different temperature 37 
conditions: 4 ºC, 25 ºC and 40 ºC using differential sedimentation.  After 12 38 
months storage at 4 and 25 °C the size of nanoparticles remained similar to 39 
those of the freshly prepared samples, whilst after storage at 40 °C there were 40 
little or no TPP-chitosan nanoparticles remaining after only 6 months.  This 41 
may be due to the decrease in molar mass of the chitosan possibly due to 42 
hydrolysis causing scission of the polymer chains, which results in a decrease 43 
in nanoparticle size and eventual disintegration. This mechanism is important 44 
in the application of TPP-chitosan as a drug delivery agent. 45 
 46 
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49 
1. Introduction 50 
Chitosan is the generic name for a family of strongly polycationic derivatives 51 
of poly-N-acetyl-D-glucosamine (chitin) extracted from the shells of 52 
crustaceans or from the mycelia of fungi (Rinaudo, 2006).  In chitosan the N-53 
acetyl group is replaced either fully or partially by NH2 and therefore the 54 
degree of acetylation can vary from DA = 0 (fully deacteylated) to DA = 1 (fully 55 
acetylated i.e. chitin).   Acetylated monomers (GlcNAc) and deacteylated 56 
monomers (GlcN) have been shown to be randomly distributed (Vårum, 57 
Anthonsen, Grasdalen, & Smidsrød, 1991a, 1991b). 58 
 59 
As the only known naturally occurring polycationic polysaccharide, chitosan, 60 
and its derivatives have received a great deal of attention from, for example, 61 
the food, cosmetic and pharmaceutical industries.  Important applications 62 
include water and waste treatment, antitumor, antibacterial and anticoagulant 63 
properties (Illum, 1998; Muzzarelli, 2009; Rinaudo, 2006).  The interaction of 64 
chitosan with mucus is also important in oral and nasal drug delivery (Davis, & 65 
Illum, 2000; Dyer, Hinchcliffe, Watts, Castile, Jabbal-Gill, Nankervis, Smith, & 66 
Illum, 2002; Harding, Davis, Deacon, & Fiebrig, 1999).  Chitosan has also 67 
been reported to enhance drug delivery across mucosal surfaces through the 68 
rearrangement of tight junction zones (Illum, 1998). 69 
 70 
Chitosan has been widely studied in the preparation of nanoparticles for drug 71 
delivery (Anitha, Deepa, Chennazhi, Tamura, & Jayakumar, 2011; Dyer et al., 72 
2002; Fernández-Urrasuno, Calvo, Rumuñán-Lopez, Vila-Jato, & Alonso, 73 
1999; Gan, & Wang, 2007; Gan, Wang, Cochrane, & McCarron, 2005; 74 
Luangtana-anan, Opanasopit, Ngawhirunpat, Nunthanid, Sriamornsak, 75 
Limmatvapirat, & Lim, 2005; Morris, Kök, Harding & Adams, 2010; Shu, & 76 
Zhu, 2000; Tsai, Bai, & Chen, 2008; Xu, & Du 2005). Nanoparticles can be 77 
prepared by the electrostatic interaction and resultant ionotropic gelation 78 
between chitosan and the tripolyphosphate (TPP) polyanion (Dyer et al., 79 
2002; Luangtana-anan et al., 2005; Janes, Calvo, & Alonso, 2001; Shu, & 80 
Zhu, 2000; Tsai, Chen, Bai, & Chen, 2011).  This interaction requires only mild 81 
conditions in terms of temperature and pH (Zhang, Oh, Allen, & Kumacheva, 82 
2004) and the nanoparticle size can be controlled by varying the chitosan: 83 
TPP ratio, pH and the molar mass of the chitosan (Hu, Pan., Sun, Hou, Ye, 84 
Hu, & Zeng, 2008; Luangtana-anan et al., 2005; Tsai et al., 2008), although a 85 
chitosan: TPP ratio of 6:1 is considered optimal (Dyer et al., 2002; Janes, et 86 
al., 2001).  Due to their sub-micron size, TPP-chitosan nanoparticles are 87 
reported to be able to penetrate into tissues via the capillaries (Gan et al., 88 
2005).  89 
 90 
The stability (shelf-life) of TPP-chitosan nanoparticles, in terms of particle 91 
size, is relevant to its potential use as a drug delivery agent as this plays an 92 
important role in the function of the nanoparticle (Berkland, King, Cox, Kim, & 93 
Pack, 2002; Hu, et al., 2008; López-León, Carvalho, Seijo, Ortega-Vinuesa, & 94 
Bastos-González, 2005; Luangtana-anan et al., 2005; Tang, Huang, & Lim, 95 
2003; Tsai et al., 2008; Tsai, et al., 2011).   Therefore it is fundamentally 96 
important to have the means available with which to measure the effects of 97 
and understand the relationships between storage conditions and stability.  98 
 99 
In this paper we will look at the stability (in terms of particle size) of TPP-100 
chitosan nanoparticles across a range of different storage temperatures: 4 ºC, 101 
25 ºC and 40 ºC.  102 
 103 
2. Materials and Methods 104 
2.1 TPP-chitosan nanoparticle preparation 105 
Chitosans (G213) from three batches (FP-002-06; FP-110-06 and FP-212-02) 106 
of DA ~ 20 % obtained from Pronova Biomedical (Oslo, Norway) and 107 
tripolyphosphate pentasodium (TPP) from Sigma Chemical Company (St. 108 
Louis, U.S.A.) were used without any further purification.  Chitosans (2.0 109 
mg/ml) and tripolyphosphate pentasodium (0.84 mg/ml) were prepared in 100 110 
ml and 40 ml of buffer (0.2 M pH 4.3 acetate), respectively.  The resultant 111 
solutions were then mixed to give an optimum TPP: chitosan ratio of ~ 1:6 (as 112 
described in Dyer et al., 2002) and the particle size distributions of the 113 
resultant nanoparticles were measured directly (t = 0). 114 
 115 
116 
2.2 Stability of TPP-chitosan nanoparticles 117 
The stability of TPP-chitosan nanoparticles was determined by measuring the 118 
particle size distribution after 12 months at 4 ºC, 25 ºC or 40 ºC. 119 
 120 
2.3 Particle size measurement 121 
Particle size distributions were determined using a DC-18000 Disc Centrifuge 122 
(CPS Instruments, Oosterhout, The Netherlands).  In order to eliminate 123 
sedimentation instability a density gradient is employed (Laidlaw, & Steinmetz, 124 
2005). The centrifuge is accelerated to 18000 rpm and solutions of decreasing 125 
sucrose concentration (8.00 %, 7.25 %, 6.50 %, 5.75 %, 5.00 %, 4.25 %, 3.50 126 
%, 2.75 % and 2.00 %) are injected on to the disc in 1.6 ml aliquots. After the 127 
gradient was stabilised (10 min) the TPP-chitosan nanoparticles (100 µl) were 128 
injected.  Each sample was preceded by the injection (100 µl) of a PVC 129 
calibration standard (377 nm). 130 
 131 
The time taken to sediment through a fluid of known density and viscosity to a 132 
known distance on the disc is related to particle size (Stokes, 1880).  Taking 133 
into account that force varies with distance from the centre of rotor during 134 
sedimentation then Stokes’ law can be expressed as follows (Laidlaw, & 135 
Steinmetz, 2005):  136 
 137 
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 139 
where D is the particle diameter (cm), η0 is the viscosity of the fluid (1.15 140 
mPas), r is the final radial displacement from the axis of rotation (cm), r0 is the 141 
initial radial displacement (cm), ρ is the particle density (1.50 g ml-1), ρ0 is the 142 
fluid density (1.02 g ml-1), ω is the rotational velocity (               ≈ 1885 rad s-1) 143 
and t is the sedimentation time (s).   144 
 145 
This expression results in a Stokes diameter and this equals the true diameter 146 
only in the case of a spherical particle; however, the correction for non-147 
60
2 rpmpi
sphericity is generally small (Laidlaw, & Steinmetz, 2005) and here we have 148 
assumed a spherical particle based on the previous evidence (Xu & Du, 149 
2005).  The advantage of this method of particle size measurement is that it is 150 
based on a mechanical as opposed to a mathematical separation and 151 
furthermore no separation medium (other than a gradient forming material) is 152 
required.     153 
 154 
2.4 Size Exclusion Chromatography coupled to Multi-Angle Light Scattering 155 
(SEC-MALS) 156 
Analytical fractionation was carried out using a series of SEC columns TSK 157 
G6000PW, TSK G5000PW and TSK G4000PW protected by a similarly 158 
packed guard column (Tosoh Bioscience, Tokyo, Japan) with on-line MALLS 159 
(Dawn DSP) and refractive index (Optilab rEX) detectors (both Wyatt 160 
Technology, Santa Barbara, U.S.A).  The eluent (0.2 M pH 4.3 acetate buffer) 161 
was pumped at 0.8 ml min-1 (PU-1580, Jasco Corporation, Great Dunmow, 162 
U.K.) and the injected volume was 100 µl (~1.0 x 10-3 g ml-1).  Absolute 163 
weight-average molar masses (Mw) were calculated using ASTRA® (Version 164 
5.1.9.1) software (Wyatt Technology, Santa Barbara, U.S.A.), at a refractive 165 
index increment, dn/dc, of 0.163 ml g-1 (Rinaudo, Milas, & Le Dung, 1993). 166 
 167 
3. Results and Discussion 168 
3.1 Chitosan molar mass 169 
Prior to their use in the preparation of nanoparticles the molar masses of the 170 
chitosan macromolecules were estimated using SEC-MALS.  Molar masses 171 
were (294000 ± 9000); (255000 ± 9000) and (322000 ± 6000) g mol-1 for FP-172 
002-06; FP-110-06 and FP-212-02, respectively (Tables 1 - 4).  As the molar 173 
mass of chitosan has been reported to have an influence on the size of the 174 
resultant nanoparticles (Luangtana-Anan et al. 2005) an aliquot of these 175 
macromolecular solutions were stored under the same conditions as the TPP-176 
chitosan nanoparticles.  The changes in molar mass (Table 1) were 177 
consistent with our previous study (Morris, Castile, Smith, Adams and 178 
Harding, 2009) in that depolymerisation is more significant at 40 °C. 179 
 180 
3.2 Fresh TPP-chitosan nanoparticles 181 
When freshly prepared, the weight-average diameters of the TPP-chitosan 182 
nanoparticles were in the range 90 – 120 nm (Tables 1 – 3 and Figures 1 – 183 
3) which is in agreement with previous studies (Anitha et al., 2011; Nasti, Zaki, 184 
de Leonardis, Ungphaiboon, Sansongsak, Rimoli, & Tirelli, 2009; Gan et al., 185 
2005; Hu et al., 2008; Xu, & Du, 2005; Zhang et al., 2004; Tsai et al., 2011). 186 
All samples had a similar turbid (milky) appearance (turbidity was only 187 
estimated visually). Considering that the three chitosan samples were from 188 
different batches some variation in molar mass and consequently in the size 189 
of the resultant nanoparticles were expected and are consistent with findings 190 
that higher molar mass chitosans produced larger nanoparticles (Luangtana-191 
anan et al. 2005; Tang, et al., 2003; Tsai et al., 2008; Tsai et al., 2011), 192 
although these differences were not significantly different and therefore we 193 
also have taken the mean values of particle size and molar mass for each 194 
storage condition (Table 4). This is still an important observation as with 195 
polysaccharide preparations batch-to-batch variation appears to be an 196 
inevitable consequence of the polydispersity of the macromolecule and it is 197 
important to determine what impact this may have on physicochemical 198 
properties in order that appropriate specifications can be defined to control the 199 
quality of the final product.  200 
 201 
3.3 Stability of TPP-chitosan nanoparticles 202 
It is clear from Figures 1 – 3 that there were few or no TPP-chitosan 203 
nanoparticles present after storage at 40 °C for 12 months and this is also 204 
reflected in their turbidity (Figure 4).  The decrease in size of the 205 
nanoparticles was evident after only 1 month storage and after 6 months the 206 
nanoparticles had essentially disappeared. This appears to be due to the 207 
decrease in molar mass of the chitosan, possibly due to hydrolysis causing 208 
scission of the polymer chains (Tables 1 - 4) which results in a decrease in 209 
nanoparticle size and eventual disintegration. Although, if decrease in molar 210 
mass was the only factor determining particle size and integrity we may have 211 
predicted that prolonged storage (6 months or more) at all the temperatures 212 
studied would have resulted in the decrease in size and eventual 213 
disappearance of nanoparticles and this is clearly not the case at 4°C and 25 214 
°C. It has been shown previously that elevated temperatures (>60 °C) have 215 
been shown to result in a decrease in size of TPP-chitosan-ascorbic acid 216 
nanoparticles (Jang, & Lee, 2008).   217 
 218 
At 4 and 25 °C the size (110 ± 40 nm) of nanoparticles remained similar to 219 
those of the freshly prepared samples. The results at 25 °C are consistent 220 
with the findings reported in Tsai et al. (2011) for nanoparticles of a similar 221 
size range, albeit in different solvent conditions. It should however be noted 222 
that we have no information as to whether the nanoparticle shape has 223 
changed during storage and this may have some bearing on the apparent 224 
particle diameter.   225 
 226 
We therefore propose that this type of nanoparticle the major cause of 227 
instability is the disintegration of the polymeric network (at higher 228 
temperatures), although we do not exclude any other mechanisms which may 229 
contribute to instability. 230 
 231 
This mechanism is important in the application of TPP-chitosan as a drug 232 
delivery agent as drug release is reported to occur in three stages – 233 
desorption of the drug molecules from the surface; diffusion of the drug 234 
molecules through pores in the nanoparticle and degradation of the polymer 235 
network (Gan, & Wang, 2007). The rates of first two are related to the size of 236 
the nanoparticle.  Furthermore the size of the nanoparticle plays an important 237 
physiological role in its in vivo interactions with biomolecules especially in the 238 
“protein corona” (Lundqvist, Stigler, Elia, Lynch, Cedervall, & Dawson, 2008). 239 
 240 
4. Conclusions 241 
The molar mass of chitosan is important in determining the size of resultant 242 
TPP-chitosan nanoparticles; higher molar mass chitosans produce larger 243 
nanoparticles.  It is important to note that three batches of the same product 244 
(G213, Pronova Biomedical, Oslo, Norway) have been studied and therefore 245 
batch-to-batch variation should be given careful consideration in the 246 
formulation of nanoparticle products, although in this case the different 247 
batches didn’t produce nanoparticles of significantly different sizes. 248 
 249 
TPP-chitosan nanoparticles are susceptible to instability via the disintegration 250 
of the polymeric network through chemical means, resulting in the total 251 
breakdown of the nanoparticle when stored for 6 months or more at 40 °C.     252 
Decreased particle size has been reported to increase the rate of drug 253 
delivery and also influences the shape of the drug release curve (Berkland et 254 
al., 2002). This suggests that in the present case drug delivery may be 255 
relatively unaffected by storage at 4 and 25 °C, whereas we may see an 256 
acceleration of the drug delivery rate after prolonged storage at 40 °C and the 257 
performance of the nanoparticles as a drug delivery vehicle is likely to be 258 
significantly affected.  We do of course realise that particle size in itself not 259 
enough to determine the stability of nanoparticles, however size is the most 260 
important (or one of the most important factors) in determining the stability of 261 
nanoparticles.  262 
 263 
Stability could potentially be improved by using freeze-drying although the 264 
resulting formulation would require a cryoprotective agent (e.g. trehalose, 265 
mannitol, etc) (Abdelwahed, Degobert, Stainmesse, & Fessi, 2006; Eriksson, 266 
Hinrichs, de Jong, Somsen, & Frijlink, 2003).   267 
 268 
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Table 1 Particle size parameters for TPP-chitosan (FP-002-06) nanoparticles 422 
on preparation (time = 0) and after storage at different temperatures (4 °C, 25 423 
°C and 40 °C) for up to 12 months and the weight-average molar mass of 424 
chitosan under the same storage conditions 425 
Time 
(months) 
Temperature 
(°C) 
Weight-
average 
Molar mass 
(gmol-1) 
Size distribution 
Weight-
average 
diameter, dw 
(nm) 
Polydispersity 
index (dw/dn) 
0 - 294000 ± 9000 91 ± 29 1.2  ± 0.1 
1 
4 304000 ± 12000 106 ± 39 1.3  ± 0.1 
25 285000 ± 9000 112 ± 42 1.4  ± 0.1 
40 308000 ± 9000 80 ± 19 1.1  ± 0.1 
3 
4 317000 ± 10000 109 ± 52 1.4  ± 0.1 
25 270000 ± 8000 115 ± 43 1.4  ± 0.1 
40 187000 ± 6000 78 ± 47 1.2  ± 0.1 
6 
4 285000 ± 6000 94 ± 31 1.3  ± 0.1 
25 213000 ± 2000 81 ± 20 1.2  ± 0.1 
40 152000 ± 2000 93 ± 70 1.3  ± 0.1 
12 
4 130000 ± 10000 111 ± 44 1.4  ± 0.1 
25 115000 ± 10000 100 ± 38 1.3  ± 0.1 
40 100000 ± 5000 104 ± 74 1.4  ± 0.1 
 426 
 427 
428 
Table 2 Particle size parameters for TPP-chitosan (FP-110-06) nanoparticles 429 
on preparation (time = 0) and after storage at different temperatures (4 °C, 25 430 
°C and 40 °C) for up to 12 months and the weight-average molar mass of 431 
chitosan under the same storage conditions 432 
Time 
(months) 
Temperature 
(°C) 
Weight-
average 
Molar mass 
(gmol-1) 
Size distribution 
Weight-
average 
diameter, dw 
(nm) 
Polydispersity 
index (dw/dn) 
0 - 255000 ± 9000 96 ± 28 1.3  ± 0.1 
1 
4 228000 ± 14000 113 ± 44 1.4  ± 0.1 
25 305000 ± 12000 120 ± 41 1.4  ± 0.1 
40 243000 ± 10000 85 ± 22 1.2  ± 0.1 
3 
4 217000 ± 7000 114 ± 50 1.4  ± 0.1 
25 317000 ± 10000 117 ± 58 1.4  ± 0.1 
40 167000 ± 7000 81 ± 36 1.2  ± 0.1 
6 
4 253000 ± 3000 94 ± 31 1.3  ± 0.1 
25 261000 ± 3000 84 ± 21 1.2  ± 0.1 
40 153000 ± 2000 5 ± 1 1.0  ± 0.1 
12 
4 130000 ± 10000 126 ± 49 1.5  ± 0.1 
25 115000 ± 10000 112 ± 48 1.4  ± 0.1 
40 100000 ± 5000 41 ± 23  7.3  ± 0.1 
 433 
 434 
435 
Table 3 Particle size parameters for TPP-chitosan (FP.212.02) nanoparticles 436 
on preparation (time = 0) and after storage at different temperatures (4 °C, 25 437 
°C and 40 °C) for up to 12 months and the weight-average molar mass of 438 
chitosan under the same storage conditions 439 
Time 
(months) 
Temperature 
(°C) 
Weight-
average 
Molar mass 
(gmol-1) 
Size distribution 
Weight-
average 
diameter, dw 
(nm) 
Polydispersity 
index (dw/dn) 
0 n.d. 322000 ± 6000 117 ± 39 1.4  ± 0.1 
1 
4 247000 ± 17000 101 ± 34 1.3  ± 0.1 
25 273000 ± 11000 122 ± 40 1.4  ± 0.1 
40 206000 ± 12000 78 ± 17 1.1  ± 0.1 
3 
4 317000 ± 10000 114 ± 50 1.4  ± 0.1 
25 278000 ± 8000 117 ± 58 1.4  ± 0.1 
40 228000 ± 8000 78 ± 50 1.1  ± 0.1 
6 
4 n.d. 94 ± 31 1.3  ± 0.1 
25 236000 ± 2000 84 ± 21 1.2  ± 0.1 
40 164000 ± 2000 n.d. n.d. 
12 
4 n.d 108 ± 38 1.4  ± 0.1 
25 115000 ± 10000 113 ± 36 1.3  ± 0.1 
40 100000 ± 5000 n.d. n.d. 
 440 
441 
Table 4 Mean particle size parameters for TPP-chitosan (G213) nanoparticles 442 
on preparation (time = 0) and after storage at different temperatures (4 °C, 25 443 
°C and 40 °C) for up to 12 months and the weight-average molar mass of 444 
chitosan under the same storage conditions 445 
Time 
(months) 
Temperature 
(°C) 
Weight-
average 
Molar mass 
(gmol-1) 
Size distribution 
Weight-
average 
diameter, dw 
(nm) 
Polydispersity 
index (dw/dn) 
0 - 290000 ± 30000 105 ± 36 1.3 ± 0.1 
1 
4 260000 ± 40000 107 ± 38 1.3 ± 0.1 
25 290000 ± 15000 119 ± 41 1.4 ± 0.1 
40 250000 ± 50000 81 ± 19 1.2 ± 0.1 
3 
4 280000 ± 60000 109 ± 48 1.4 ± 0.1 
25 290000 ± 20000 122 ± 50 1.4 ± 0.1 
40 195000 ± 20000 79 ± 43 1.2 ± 0.1 
6 
4 270000 ± 20000 94 ± 30 1.3 ± 0.1 
25 235000 ± 20000 81 ± 21 1.2 ± 0.1 
40 160000 ± 5000 9 ± 1 1.0 ± 0.1 
12 
4 130000 ± 10000 115 ± 46 1.4 ± 0.1 
25 115000 ± 10000 110 ± 41 1.3 ± 0.1 
40 100000 ± 5000   n.d. 1.6 ± 0.1 
 446 
447 
Legends to Figures 448 
449 
Figure 1 mean particle size distributions for TPP-chitosan nanoparticles:   450 
 fresh nanoparticles  451 
 stored at 4 °C for 1 month  452 
 stored at 4 °C for 3 months 453 
 stored at 4 °C for 6 months 454 
 stored at 4 °C for 12 months. 455 
 456 
457 
Figure 2 mean particle size distributions for TPP-chitosan nanoparticles:   458 
 fresh nanoparticles  459 
 stored at 25 °C for 1 month  460 
 stored at 25 °C for 3 months 461 
 stored at 25 °C for 6 months 462 
 stored at 25 °C for 12 months. 463 
 464 
465 
Figure 3 mean particle size distributions for TPP-chitosan nanoparticles:   466 
 fresh nanoparticles  467 
 stored at 40 °C for 1 month  468 
 stored at 40 °C for 3 months 469 
 stored at 40 °C for 6 months 470 
 stored at 40 °C for 12 months. 471 
 472 
473 
Figure 4 visual representation of the turbidity of the TPP-chitosan 474 
nanoparticle suspensions after 12 months storage at 4 °C, 25 °C and 40 °C 475 
(from left-to-right). 476 
